NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study

Reuters

10/20

NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study

NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma $(RCC)$ patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576785960"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576785960\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576785960?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576785960","market":"fut","top_or_hot":-1,"title":"NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma <a href=\"https://laohu8.com/S/RCC\">$(RCC)$</a> patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-20 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma <a href=\"https://laohu8.com/S/RCC\">$(RCC)$</a> patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NCNA","symbol_name":"Nucana PLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL6mg3Qh:1","article_id":"2576785960","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576785960","pubTimestamp":1760961686,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology  Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma  patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NCNA":"Nucana PLC","BK4139":"生物科技"},"translate_title":"NuCana报告NUC-7738联合PD-1抑制剂在癌症研究中取得有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NCNA":0.9},"content_text":"NuCana Reports Promising Results for NUC-7738 in Combination with PD-1 Inhibitors in Cancer Study\n    \n\n        NuCana plc has announced encouraging new data on its investigational drug NUC-7738, studied in combination with PD-1 inhibitors. The company presented these results at the European Society for Medical Oncology (ESMO) Congress 2025. The research used primary patient-derived organoids and autologous tumor-infiltrating lymphocytes from renal cell carcinoma $(RCC)$ patients, demonstrating that NUC-7738 may enhance the effectiveness of PD-1 inhibitors by increasing tumor cell death. The findings support the mechanism of action of NUC-7738 and align with ongoing results from the Phase 1/2 NuTide:701 clinical study, which is evaluating NUC-7738 in patients with PD-1 inhibitor-resistant melanoma. NuCana is currently recruiting additional patients for the NuTide:701 study and plans to discuss the data with the U.S. Food and Drug Administration to determine the optimal registration strategy for potential marketing approval.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-243050), on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}